Raymond James Financial’s AbCellera Biologics ABCL Stock Holding History

Raymond James Financial’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261K	Sell	33,200 -256,636	-89%	-$1.25M	﹤0.01%	4907
2026 Q1	$1.01M	Buy	289,836 +42,786	+17%	+$154K	﹤0.01%	3832
2025 Q4	$845K	Buy	247,050 +208,632	+543%	+$931K	﹤0.01%	3892
2025 Q3	$193K	Buy	38,418 +10,369	+37%	+$45.7K	﹤0.01%	4632
2025 Q2	$96.2K	Buy	28,049 +4,070	+17%	+$10.1K	﹤0.01%	4892
2025 Q1	$53.5K	Buy	23,979 +4,478	+23%	+$12.8K	﹤0.01%	4636
2024 Q4	$57.1K	Buy	+19,501	New	+$54.3K	﹤0.01%	4593

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Raymond James Financial's ABCL Position: Q2 2026 in Review

Raymond James Financial reduced its AbCellera Biologics (ABCL) stake by 89% in Q2 2026, selling an estimated $1.25M and leaving 33,200 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #4907.

Raymond James Financial first reported a position in ABCL in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.01M in Q1 2026. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Raymond James Financial held 33,200 shares of AbCellera Biologics worth $261K as of Q2 2026.
Raymond James Financial sold 256,636 AbCellera Biologics shares in Q2 2026, an estimated $1.25M.
AbCellera Biologics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4907 holding.
Raymond James Financial first reported a position in AbCellera Biologics in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's AbCellera Biologics position peaked at $1.01M in Q1 2026.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.